221 related articles for article (PubMed ID: 9835515)
1. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.
Seifer M; Hamatake RK; Colonno RJ; Standring DN
Antimicrob Agents Chemother; 1998 Dec; 42(12):3200-8. PubMed ID: 9835515
[TBL] [Abstract][Full Text] [Related]
2. Antiviral efficacy of lobucavir (BMS-180194), a cyclobutyl-guanosine nucleoside analogue, in the woodchuck (Marmota monax) model of chronic hepatitis B virus (HBV) infection.
Genovesi EV; Lamb L; Medina I; Taylor D; Seifer M; Innaimo S; Colonno RJ; Clark JM
Antiviral Res; 2000 Dec; 48(3):197-203. PubMed ID: 11164506
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Anti-hepatitis B Virus Activity of 2',3'-Dideoxyguanosine.
Zhang P; Zhai S; Chang J; Guo JT
Virol Sin; 2018 Dec; 33(6):538-544. PubMed ID: 30421112
[TBL] [Abstract][Full Text] [Related]
5. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.
Levine S; Hernandez D; Yamanaka G; Zhang S; Rose R; Weinheimer S; Colonno RJ
Antimicrob Agents Chemother; 2002 Aug; 46(8):2525-32. PubMed ID: 12121928
[TBL] [Abstract][Full Text] [Related]
6. Carbonyl J acid derivatives block protein priming of hepadnaviral P protein and DNA-dependent DNA synthesis activity of hepadnaviral nucleocapsids.
Wang YX; Wen YM; Nassal M
J Virol; 2012 Sep; 86(18):10079-92. PubMed ID: 22787212
[TBL] [Abstract][Full Text] [Related]
7. Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies.
Zoulim F; Berthillon P; Guerhier FL; Seigneres B; Germon S; Pichoud C; Cheng YC; Trepo C
J Gastroenterol Hepatol; 2002 Dec; 17 Suppl():S460-3. PubMed ID: 12534778
[TBL] [Abstract][Full Text] [Related]
8. Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine.
Jones SA; Murakami E; Delaney W; Furman P; Hu J
Antimicrob Agents Chemother; 2013 Sep; 57(9):4181-9. PubMed ID: 23774432
[TBL] [Abstract][Full Text] [Related]
9. Main properties of duck hepatitis B virus DNA polymerase: comparison with the human and woodchuck hepatitis B virus DNA polymerases.
Fourel I; Hantz O; Cova L; Allaudeen HS; Trepo C
Antiviral Res; 1987 Nov; 8(4):189-99. PubMed ID: 3446017
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine.
Severini A; Liu XY; Wilson JS; Tyrrell DL
Antimicrob Agents Chemother; 1995 Jul; 39(7):1430-5. PubMed ID: 7492080
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses.
Seignères B; Pichoud C; Martin P; Furman P; Trépo C; Zoulim F
Hepatology; 2002 Sep; 36(3):710-22. PubMed ID: 12198665
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.
Walsh AW; Langley DR; Colonno RJ; Tenney DJ
PLoS One; 2010 Feb; 5(2):e9195. PubMed ID: 20169198
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection.
Genovesi EV; Lamb L; Medina I; Taylor D; Seifer M; Innaimo S; Colonno RJ; Standring DN; Clark JM
Antimicrob Agents Chemother; 1998 Dec; 42(12):3209-17. PubMed ID: 9835516
[TBL] [Abstract][Full Text] [Related]
14. Priming of duck hepatitis B virus reverse transcription in vitro: premature termination of primer DNA induced by the 5'-triphosphate of fialuridine.
Staschke KA; Colacino JM
J Virol; 1994 Dec; 68(12):8265-9. PubMed ID: 7525986
[TBL] [Abstract][Full Text] [Related]
15. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.
Jacquard AC; Brunelle MN; Pichoud C; Durantel D; Carrouée-Durantel S; Trepo C; Zoulim F
Antimicrob Agents Chemother; 2006 Mar; 50(3):955-61. PubMed ID: 16495257
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human and duck hepatitis B virus by 2',3'-dideoxy-3'-fluoroguanosine in vitro.
Schröder I; Holmgren B; Oberg M; Löfgren B
Antiviral Res; 1998 Jan; 37(1):57-66. PubMed ID: 9497073
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir.
Shaw T; Mok SS; Locarnini SA
Hepatology; 1996 Nov; 24(5):996-1002. PubMed ID: 8903366
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine.
Tatti KM; Korba BE; Stang HL; Peek S; Gerin JL; Tennant BC; Schinazi RF
Antiviral Res; 2002 Jul; 55(1):141-50. PubMed ID: 12076758
[TBL] [Abstract][Full Text] [Related]
19. The mechanism of inhibition of hepatitis B virus replication by the carbocyclic analog of 2'-deoxyguanosine.
Price PM; Banerjee R; Jeffrey AM; Acs G
Hepatology; 1992 Jul; 16(1):8-12. PubMed ID: 1319957
[TBL] [Abstract][Full Text] [Related]
20. Perspectives for the treatment of hepatitis B virus infections.
De Clercq E
Int J Antimicrob Agents; 1999 Jul; 12(2):81-95. PubMed ID: 10418752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
